
    
      Confirm clinical safety and identify clinical response rate of combination treatment with
      curcumin and 5FU in chemorefractory CRC patients. To determine whether curcumin
      administration induces systemic alterations in inflammatory and epigenetic biomarkers in
      patients with chemoresistant metastatic colorectal cancer (CRC). To correlate altered
      biomarker findings with clinical response according to RECIST V1.1 and survival criteria.
    
  